Understanding aggressive prostate cancer in high-risk and African American men
Project #1
['FUNDING_OTHER'] · HOWARD UNIVERSITY · NIH-11196094
This project will analyze tumor and genetic differences in metastatic prostate cancer to help high-risk men—especially African American men—get better prognoses and more tailored care.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HOWARD UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11196094 on ClinicalTrials.gov |
What this research studies
Researchers at Howard University and Johns Hopkins will build a cohort of men with locally metastatic prostate cancer, prioritizing high-risk and African American patients, and collect tumor samples and clinical information. They will perform genomic and epigenomic profiling and use tissue-based assays to measure tumor and immune microenvironment features. The team will compare primary and metastatic tumors and link molecular patterns to clinical outcomes and genetic ancestry. Findings aim to identify biomarkers that signal aggressive, lethal disease and could guide future personalized treatments.
Who could benefit from this research
Good fit: Ideal candidates are men with locally metastatic prostate cancer who can provide tumor tissue and clinical data, with outreach focused on high-risk and African American patients.
Not a fit: Men with only early-stage localized prostate cancer who cannot provide metastatic tissue or clinical follow-up data may not directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify biomarkers that better predict which prostate cancers are likely to be deadly and point to more personalized treatment or monitoring for high-risk men.
How similar studies have performed: Previous research has shown ancestry-linked genomic and immune differences in prostate tumors, but translating those findings into reliable clinical biomarkers remains largely unproven.
Where this research is happening
WASHINGTON, UNITED STATES
- HOWARD UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUDSON, TAMARO SYTON — HOWARD UNIVERSITY
- Study coordinator: HUDSON, TAMARO SYTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer